ReviewKidney international2009
Epigenetics and the control of epithelial sodium channel expression in collecting duct.
Review in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Epigenetic DNA Methylation and Protein Homocysteinylation: Key Players in Hypertensive Renovascular Damage.International journal of molecular sciences · 2024Review
- A novel role of DOT1L in kidney diseases.Molecular biology reports · 2023Review
- Epigenetic modification in diabetic kidney disease.Frontiers in endocrinology · 2023Review
- Protein Methylation in Diabetic Kidney Disease.Frontiers in medicine · 2022Review
- Article
- Epigenetic modification: a regulatory mechanism in essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Review
- Epigenetic Biomarkers in Cardiovascular Diseases.Frontiers in genetics · 2019Review
- Epigenetic Mechanisms and Hypertension.Hypertension (Dallas, Tex. : 1979) · 2018Review
- Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang.Bioscience reports · 2018Article
- Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genome-wide association studies.Journal of human hypertension · 2017Review
- Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead.Current cardiology reports · 2017Review
- The Epigenetic Machinery in Vascular Dysfunction and Hypertension.Current hypertension reports · 2017Review
- Serum and Glucocorticoid Regulated Kinase 1 in Sodium Homeostasis.International journal of molecular sciences · 2016Review
- Hypertensive epigenetics: from DNA methylation to microRNAs.Journal of human hypertension · 2015Review
- Recent developments in epigenetics of acute and chronic kidney diseases.Kidney international · 2015Review
- Epigenetic mechanisms in heart development and disease.Drug discovery today · 2015Review
- Environmental origins of hypertension: phylogeny, ontogeny and epigenetics.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Review
- Use of epigenetic drugs in disease: an overview.Genetics & epigenetics · 2014Review
- Histone lysine methylation in diabetic nephropathy.Journal of diabetes research · 2014Review
- Epigenomics of hypertension.Seminars in nephrology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
In eukaryotic nuclei, genomic DNA is compacted with histone and nonhistone proteins into a dynamic polymer termed chromatin. Reorganization of chromatin structure through histone modifications, the action of chromatin factors, or DNA methylation, can profoundly change gene expression. These epigenetic modifications allow heritable and potentially reversible changes in gene functioning to occur without altering the DNA sequence, thus extending the information potential of the genetic code. This review provides an introduction to epigenetic concepts for renal investigators and an overview of our work detailing an epigenetic pathway for aldosterone signaling and the control of epithelial Na(+) channel-alpha (ENaCalpha) subunit gene expression in the collecting duct. This new pathway involves a nuclear repressor complex, consisting of histone H3 Lys-79 methyltransferase disruptor of telomeric silencing-1a (Dot1a), ALL1 fused gene from chromosome 9 (Af9), a sequence-specific DNA-binding protein that binds the ENaCalpha promoter, and potentially other nuclear proteins. This complex regulates targeted histone H3 Lys-79 methylation of chromatin associated with the ENaCalpha promoter, thereby suppressing its transcriptional activity. Aldosterone disrupts the Dot1a-Af9 interaction by serum- and glucocorticoid-induced kinase-1 phosphorylation of Af9, and inhibits Dot1a and Af9 expression, resulting in histone H3 Lys-79 hypomethylation at specific subregions, and derepression of the ENaCalpha promoter. The Dot1a-Af9 pathway may also be involved in the control of genes implicated in renal fibrosis and hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.